Hookworm
Candidate for First Human Hookworm Vaccine Enters Phase 1 Clinical Trial in Brazil
January 19, 2012
WASHINGTON, DC-- Jan. 19, 2012--The Sabin Vaccine Institute (Sabin) today announced the start of a Phase 1 clinical trial of its Na-GST-1 antigen, a candidate for the first human hookworm vaccine. The trial is a major milestone for the vaccine product development partnership (PDP) headquartered at Sabin.
This trial advances Sabin’s goal to develop a safe, efficacious and low-cost vaccine to reduce the global burden of human hookworm, which infects nearly 600 million people worldwide.
Major Funding Announced to Continue the Development of a Vaccine for Leading Disease Affecting Global Poor
June 22, 2011
Bill & Melinda Gates Foundation to Provide Sabin Vaccine Institute with $12 Million to Fund Multiple Phase 1 Clinical Trials and Further Product Development for Human Hookworm Vaccine
Sabin Vaccine Institute (Sabin) today announced receipt of a two-year, $12 million grant from the Bill & Melinda Gates Foundation to continue development of a vaccine to prevent human hookworm infection, a parasitic disease that affects 600 million people worldwide.
BCM, Texas Children’s announce recruitment of Dr. Peter Hotez and team in major advance to develop vaccines for world’s poor
June 8, 2011
Leaders of the Sabin Vaccine Institute, Baylor College of Medicine and Texas Children’s Hospital today announced an agreement to move Sabin’s vaccine development program to Texas Children’s and BCM as part of the recruitment of world renowned neglected diseases expert Dr. Peter Hotez.
Print this page
Email this page